Trefoil Therapeutics presents accelerated healing of corneal endothelial lesions by engineered fibroblast growth factor at ARVO 2020.
Read More
News and Events
All news
Filter by:
Search
Year
Trefoil Therapeutics Appoints Thomas M. Tremblay, RN BSN, Vice President, Clinical Development
Experienced clinical development executive to lead the TTHX1114 clinical study in corneal endothelial disease.
Read MoreTrefoil Therapeutics Selects AGB Biologics tp Supply Lead Compound TTHX1114
AGC selected based on their proven cGMP capabilities as a manufacturer of protein based therapeutics.
Read MoreLead candidate TTHX1114 will advance to IND and clinical study in corneal endothelial disease in early 2020.
Read MoreTrefoil Therapeutics Elects Benjamin F. McGraw, III, to its Board of Directors
As the company’s eFGF-1 platform moves forward, Dr. McGraw brings significant high-level experience in development and commercialization.
Read MoreTrefoil Therapeutics Raises $5.2 Million Series 1 Financing
Hatteras Venture Partners leads round which provides funding to reach IND filing for novel corneal endothelial dystrophy therapy.
Read MoreTRND Award Will Accelerate the Development of a New Therapy for Fuchs Dystrophy
Read MoreExpands Research from Endothelial to Epithelial Cell Regeneration
Read MoreEngineered FGF-1 Derivatives Stimulate Proliferation of Corneal Endothelial Cells
Read MoreDevelopment Program to Focus on the Treatment of Corneal Dystrophies
Read More